SXTC SXTC
Company Profile ↓Company Overview
SXTC (SXTC) is a publicly traded company listed on with a market capitalization of $67.07K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Mar 2026 Revenue of $1.14M (-34.6% YoY); net profit $-6.21M.
- Trailing 12 Months Year-on-year growth — revenue -34.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -16.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -16.74% |
| 1 Year: | -34.63% |
Stock Price Performance
| 1 Year: | -99.97% |
| 6 Months: | -98.52% |
| 3 Months: | -96.26% |
| 1 Month: | -97.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)22.57 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -16.7% CAGR over 5 years.
- Trading 100.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1.97M | 1.93M | 1.74M | 1.14M |
| Cost of Revenue | - | 1.55M | 1.37M | 1.37M | 889.35K |
| Gross Profit | - | 426.27K | 553.97K | 367.43K | 248.70K |
| Operating Expenses | - | 6.03M | 3.07M | 3.05M | 7.37M |
| Operating Income | - | -5.61M | -2.52M | -2.68M | -7.12M |
| EBITDA | - | -5.21M | -2.28M | -2.50M | -6.00M |
| Interest Expense | - | 476.78K | 544.28K | 648.22K | 62.97K |
| Pretax Income | - | -5.93M | -3.10M | -3.30M | -6.21M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -5.93M | -3.10M | -3.30M | -6.21M |
| Diluted EPS | -85,613.36 | -15,576.83 | -1,676.69 | -348.17 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 29.55M | 23.13M | 21.66M | 34.75M |
| Current Assets | - | 19.52M | 14.23M | 21.30M | 34.51M |
| Cash & Equivalents | - | 17.37M | 12.07M | 18.10M | 28.18M |
| Inventory | - | 531.25K | 794.86K | 828.05K | 777.06K |
| Receivables | - | 1.34M | 1.31M | 1.30M | 931.57K |
| Total Liabilities | - | 14.86M | 9.20M | 6.22M | 5.05M |
| Current Liabilities | - | 14.50M | 8.90M | 6.01M | 4.35M |
| Long Term Debt | - | 117.86K | 117.13K | 96.26K | 644.39K |
| Total Debt | - | 3.76M | 2.65M | 983.88K | 1.12M |
| Total Equity | - | 14.69M | 13.93M | 15.44M | 29.71M |
| Shares Outstanding | - | 381 | 1.85K | 91.75K | 958.08K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -80.76K | -1.93M | -2.35M | -4.02M |
| Investing Cash Flow | - | -12.30K | 26.42K | 63.52K | -1.25M |
| Financing Cash Flow | - | 2.94M | -2.62M | 8.40M | 14.43M |
| Capital Expenditure | - | -70.68K | -7.06K | -2.02K | -1.25M |
| Free Cash Flow | - | -151.44K | -1.94M | -2.35M | -5.27M |
| Net Change in Cash | - | 2.85M | -4.53M | 6.12M | 9.17M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 21.6% | 28.7% | 21.1% | 21.9% |
| Operating Margin % | - | -284.4% | -130.4% | -154.0% | -625.9% |
| Net Margin % | - | -301.0% | -160.7% | -189.8% | -545.2% |
| ROE % | - | -40.4% | -22.2% | -21.4% | -20.9% |
| ROCE % | - | -37.2% | -17.7% | -17.1% | -23.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SXTC
China SXT will combine every 80 shares into one Aug. 10 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQbU1WSUJmX3VRMWZ2X0RPLXhHYWpVVExzTUlZc0J2NDktelNvVUJmSkh6OUVKaUktbW5QbHZmRURIODlVaFBJLXVVRlBsU1hJeGIwU0JhWDZETV9SOXJUVXJ1UjVEbld4QkNwcUlvY0lqNDdtc0NnRjNYNTg4a3BYcDRWRUJzY0dQMjZ1RH…
China SXT Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTC - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE41WTR0TFdwVDk1VUNtSVNCcE03NEpsNE5zR20tX2Y2MWR4ODFDdGZWOTNwRmlSa2hYYWtKUEF3bmp1NlZ5SC1VcnU5QVNWT1hEX1dIYTdLVWNQNlNPZEg2c3E1UXU0VnhHVWYyN29xc1liQ0lSd3Q0?oc=5" target="_blank">China S…
China SXT Pharmaceuticals, Inc. Announces Share Consolidation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOMDFZa2xWYzNUNkN3NTJuaXFJaVk4R19EdEN0Tm8zT1hsbGFtd3VLUGNReENRNTEtNDRlcGZpVEJvZGtXQU5XcDdvVlhNYkJ2VWw4T3VFT2o1S3NPb3RTRGYwY2hucnZIVEdwZ2ZXRUU2a1h4dXU5UnZnSXZtVlB5RkRhczBqMTFza3JzYS…
Why China SXT Pharmaceuticals (SXTC) Stock Is Down Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOT2ZudE1OUERQTmtKbzNSV0JCQnZLMGpWS0N3RlBjbjZoM19hMUJMS3VYSTRGN2pHdTU3dXZhNXVZNkhfTlpUeEtuWm9NNFV5bE9DM3FpbEQyYzNUbHRROWg4aTlKaGR1Y3I2NElObzE4M0t3VUFwamt5SUE0ZFdhak5vbUJxTklCQ0lvcU…
SXTC Stock Slumps As Massive Resale Overhang Hits The Tape - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOZ1hJTGlrVkpTNkNHMUtuM1FydDh5a3kwRUx3WHZVSzlKaFpzcGNaX2duMEY0a0NVblYyRklrR0ktXzU3S2Zac2FrZHRtaTBoWVNDS0xKODNIOVZFU29yNkxtS243SkFhbWdCcXBqTzY4SkJhWHE4SnlmU1BuQ09wZHRBSVNHVFJHaVE?oc…
What's going on in today's after hours session - ChartMill
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPUmlGa2NJT2NjcC00dlRIWWpiX2lrYzlEVS10RVBodm1HWW5YeXVCUk1yR2RYcTJ1TG00TFBvU25uRWNOSjY1Y2FYTnlHeDRsOU00SE5GRFlZN0pxeU5QYkh2dkxsLUxwZzdud0R0WVRpQzhJSjRCTWxaZkswbmxCbHNkeTZKaGcwTDdvaD…
SXTC — Frequently Asked Questions
What is the current share price of SXTC?
As of 2026-08-05 17:25 PDT, SXTC trades at $0.07 on NASDAQ/NYSE. Its 52-week range is $0.05 to $300.00.
What is the market capitalisation of SXTC?
SXTC has a market capitalisation of $67.07K on NASDAQ/NYSE.
What is the return on equity (ROE) of SXTC?
SXTC has a return on equity (ROE) of -20.89%. Its return on capital employed (ROCE) is -23.43%.
Is SXTC a good stock to buy?
This page provides a data-driven analysis of SXTC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.